35. Implementation of Guidelines in Patients with St-Segment Elevation Myocardial Infarction Admitted at National Institute of Cardiovascular Diseases Karachi
Mahboob Ali, Shahbaz Ali Shaikh, Sarfraz Hussain Sahito, Muhammad Aslam, Faraz Farooq Memon and Javed Khurshed Shaikh
ABSTRACT
Objective: To determine implementation of guidelines recommended pharmacological (disease modifying) and reperfusion therapy in patients with ST- Segment Elevation Myocardial Infarction (STEMI).
Study Design: Cross-sectional study.
Place and Duration of Study: This study was conducted at the at National Institute of Cardiovascular Diseases Karachi from January 2019 to September 2020.
Materials and Methods: All 200 patients with diagnosis of acute STEMI were evaluated. Information collected included baseline ECG and cardiac markers, reperfusion therapy i.e. fibrinolytic or primary percutaneous coronary intervention, medications prescribed in the first 24 hours of admission and at the time of discharge.
Results: Among 200 patients’ aspirin was administered to 200 (100%) at admission and discharge. 176 (88.6%), 198(99.0%) received oral beta-blockers at admission and discharge. (ACEI) or ARBS were administered in 172(86.0%), 196(98.0%) at admission and discharge. Lipid-lowering therapy was prescribed in 199(99.5%) patients. No patients received fibrinolytic (streptokinase). 200 (100%) patient underwent primary percutaneous intervention.
Conclusion: We concluded that almost 99% of Patients with STEMI received recommended disease modifying pharmacological therapy i.e. Aspirin, Beta blocker statins, ACE inhibitors and 100% trend towards primary percutaneous coronary intervention. However, as majority of our patients are unprivileged & unaware of their disease.
Key Words: Acute coronary syndrome, ST-segment Elevation Myocardial Infarction
Citation of article: Ali M, Shaikh SA, Sahito SH, Aslam M, Memon FF, Shaikh JK. Implementation of Guidelines in Patients with St-Segment Elevation Myocardial Infarction Admitted at National Institute of Cardiovascular Diseases Karachi. Med Forum 2021;32(6):142-146.